InvestorsHub Logo
Followers 128
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: BioSpecialist post# 620758

Friday, 12/23/2016 3:36:43 PM

Friday, December 23, 2016 3:36:43 PM

Post# of 640630
RDHL the next big higherflyer in the bio sector

RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html

The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------

Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.